MRNA Stock: Price, Forecast, Financials & AI Analysis

Loading...

01/14 15:52

MRNA Stock: Price, Forecast, Financials & AI Analysis

High

41.980

Open

39.730

VWAP

0.28

Vol

16.59M

Mkt Cap

15.47B

Low

39.320

Amount

4.68M

EV/EBITDA(TTM)

--

Total Shares

390.68M

EV

11.02B

EV/OCF(TTM)

--

P/S(TTM)

6.88

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Show More

Events Timeline

(ET)

2026-01-14

14:40:00

New

Moderna Shares Rise 2.3% to $40.51

2026-01-13 (ET)

2026-01-13

12:10:00

Moderna Stock Rises 12.9% to $38.21

2026-01-13

10:20:00

Moderna Shares Rise 7.92% to $36.52

2026-01-13

10:00:00

Moderna and Others See Notable Gains This Morning

2026-01-12 (ET)

2026-01-12

16:50:00

Moderna Stock Shows Moderate Bullish Activity Near $33.89

2026-01-12

08:00:00

Moderna Reiterates 10% Revenue Growth Target for 2026

2026-01-12

08:00:00

Moderna Expects 10% Revenue Growth in 2026

2026-01-09 (ET)

2026-01-09

16:30:00

Moderna Shares Up 1.39% with Active Options Trading

News

an image of Benzinga

PinnedModerna (MRNA) Projects $1.9B Revenue for 2025, Cuts Operating Expenses by $200M

an image of seekingalpha

13:11 PMseekingalpha

BofA Reports 85% of Market Short Interest from Hedge Funds, MRNA at 17.4%

an image of Benzinga

02:03 AMBenzinga

Intel Corp (INTC) Stock Rises 7.33% to $47.29 Driven by Strong AI Server Demand

an image of NASDAQ.COM

01:04 AMNASDAQ.COM

S&P 500 Index ($SPX) Declines 0.19% as Software Stocks Retreat

an image of Barron's

00:55 AMBarron's

Stocks Decline Following JPMorgan's Underwhelming Earnings Announcement

an image of Barron's

U.S. Markets Fell on Tuesday; Regencell Bioscience Suffered the Largest Loss

20 Analyst Rating

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 40.13 USD with a low forecast of 17.00 USD and a high forecast of 198.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

13 Hold

4 Sell

Hold

Current: 0.000

Low

17.00

Averages

40.13

High

198.00

Current: 0.000

Low

17.00

Averages

40.13

High

198.00

Wedbush

Outperform

maintain

$26 -> $37

Al Analysis

2026-01-07

Reason

Wedbush

Price Target

$26 -> $37

Al Analysis

2026-01-07

maintain

Outperform

Reason

Wedbush raised the firm's price target on Monte Rosa Therapeutics to $37 from $26 and keeps an Outperform rating on the shares after the company announced positive interim data from an ongoing Phase 1 clinical study evaluating MRT-8102 for the treatment of inflammatory conditions. Monte Rosa also expects to initiate a Phase 2 study in atherosclerotic cardiovascular disease patients in 2026, and is currently evaluating additional potential indications including metabolic dysfunction-associated steatohepatitis, gout, and recurrent pericarditis, notes the analyst, who is updating the firm's model to include credit for ASCVD for MRT-8102.

LifeSci Capital

analyst

Outperform

maintain

2026-01-07

Reason

LifeSci Capital

analyst

Price Target

2026-01-07

maintain

Outperform

Reason

After Monte Rosa announced an update with data from the placebo-controlled Phase 1 trial testing their NEK7-targeted molecular glue degrader, called MRT-8102, LifeSci Capital says that today's initial data will continue to "strongly support investor interest" in the NEK7 MGD program. Given the importance of hsCRP reductions across a range of cardiovascular diseases, it's "not a tremendous surprise to us that the stock is up pre-market," adds the analyst, who has an Outperform rating and a "favorable view on today's dataset."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for MRNA

Unlock Now

Valuation Metrics

The current forward P/E ratio for Moderna Inc (MRNA.O) is -3.67, compared to its 5-year average forward P/E of -1.87. For a more detailed relative valuation and DCF analysis to assess Moderna Inc 's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

an image of dotted line Image

N/A

5Y Average PE

-1.87

Current PE

-3.67

Overvalued PE

11.46

Undervalued PE

-15.20

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

an image of dotted line Image

N/A

5Y Average EV/EBITDA

-2.04

Current EV/EBITDA

-2.40

Overvalued EV/EBITDA

7.69

Undervalued EV/EBITDA

-11.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

an image of dotted line Image

5Y Average PS

6.24

Current PS

6.29

Overvalued PS

8.97

Undervalued PS

3.51

Financials

Al Analysis

Annual

Quarterly

Trading Trends

People Also Watch

Frequently Asked Questions

What is Moderna Inc (MRNA) stock price today?

The current price of MRNA is 40.92 USD — it has increased 3.33 % in the last trading day.

What is Moderna Inc (MRNA)'s business?

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

What is the price predicton of MRNA Stock?

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is40.13 USD with a low forecast of 17.00 USD and a high forecast of 198.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Moderna Inc (MRNA)'s revenue for the last quarter?

Moderna Inc revenue for the last quarter amounts to 1.02B USD, decreased -45.44 % YoY.

What is Moderna Inc (MRNA)'s earnings per share (EPS) for the last quarter?

Moderna Inc. EPS for the last quarter amounts to -0.51 USD, decreased -1800.00 % YoY.

How many employees does Moderna Inc (MRNA). have?

Moderna Inc (MRNA) has 5800 emplpoyees as of January 14 2026.

What is Moderna Inc (MRNA) market cap?

Today MRNA has the market capitalization of 15.47B USD.